Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Clinical trial NCT01696045 · TERMINATED
Trial details
- NCT number
- NCT01696045
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-12
- Primary completion
- 2016-07-31
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.